Cabilatazan, Ricky C.
HRN: 25-51-26 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/22/2024
CEFUROXIME 750MG (VIAL)
08/22/2024
08/28/2024
IV
750mg
TID
Infected Wound PAOD
Waiting Final Action
Indication: Empiric Type of Infection: Bone & JointSkin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes